Capital International Investors
NAMS icon

Capital International Investors’s NewAmsterdam Pharma NAMS Stock Holding History

Capital International Investors’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.4M Buy
1,723,495
+282,364
+20% +$9.3M 0.01% 343
2026
Q1 		$46.1M Sell
1,441,131
-621,404
-30% -$20.2M 0.01% 340
2025
Q4 		$72.4M Hold
2,062,535
– – 0.01% 323
2025
Q3 		$58.7M Hold
2,062,535
– – 0.01% 332
2025
Q2 		$37.4M Hold
2,062,535
– – 0.01% 353
2025
Q1 		$42.2M Hold
2,062,535
– – 0.01% 334
2024
Q4 		$53M Buy
+2,062,535
New +$43.8M 0.01% 336

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Capital International Investors's NAMS Position: Q2 2026 in Review

Capital International Investors increased its NewAmsterdam Pharma (NAMS) stake by 20% in Q2 2026, buying an estimated $9.3M and bringing the position to 1,723,495 shares worth $58.4M. The position accounts for 0.01% of the portfolio, ranked #343.

Capital International Investors first reported a position in NAMS in Q4 2024 and has held it in 7 quarters since. The position peaked at $72.4M in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Capital International Investors held 1,723,495 shares of NewAmsterdam Pharma worth $58.4M as of Q2 2026.
  • Capital International Investors bought 282,364 NewAmsterdam Pharma shares in Q2 2026, an estimated $9.3M.
  • NewAmsterdam Pharma made up 0.01% of Capital International Investors's portfolio in Q2 2026, its #343 holding.
  • Capital International Investors first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 7 quarters since.
  • Capital International Investors's NewAmsterdam Pharma position peaked at $72.4M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Capital International Investors's 13F filing for Q2 2026, filed 12 Aug 2026.